Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB
Mandate

Vinge advises Ultimovacs AS on its acquisition of the immunotherapy business of Immuneed AB

September 03, 2018 M&A

Vinge together with the Norwegian law firm Schjodt advises the Norwegian pharmaceuticals company Ultimovacs AS in connection with its acquisition of the immunotherpay business of the Uppsala based company Immuneed AB.

The business focuses on the development of vaccine for the treatment and potential prevention of cancer.

Vinge's team consisted primarily of the partner Jonas Johansson and the associates Carl Sander and Fredric Reismüller.

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

 Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

 Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

 Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026